TP53 and cancer: The protein-deacetylating activities of both sirtuin-1 and sirtuin-2 can be inhibited simultaneously by the small molecules tenovin-1/-6 or sirtinol (with no effects on other sirtuins and Zn2+-dependent HDACs), which are currently being targeted as potential therapeutic agents for cancer since they induce p53-dependent proapoptotic activity in malignant cells while having no effect on normal cells [239,240].